Jeffrey G Weiner1, Andrea N Lambert2, Cary Thurm3, Matt Hall3, Jonathan H Soslow2, Tyler E Reimschisel4, David W Bearl2, Debra A Dodd2, Brian Feingold5, Justin Godown2. 1. Department of Pediatric Cardiology, Monroe Carell Jr. Children's Hospital, Nashville, TN. Electronic address: jeffrey.g.weiner@vumc.org. 2. Department of Pediatric Cardiology, Monroe Carell Jr. Children's Hospital, Nashville, TN. 3. Children's Hospital Association, Lenexa, KS. 4. Department of Pediatrics, Monroe Carell Jr. Children's Hospital, Nashville, TN. 5. Department of Pediatrics and Clinical and Translational Science, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Abstract
OBJECTIVES: To compare the outcomes and comorbidities of children with mitochondrial disease undergoing heart transplantation with children without mitochondrial disease. STUDY DESIGN: Using a unique linkage between the Pediatric Health Information System and Scientific Registry of Transplant Recipients databases, pediatric heart transplantation recipients from 2002 to 2016 with a diagnosis of cardiomyopathy were included. Post heart transplantation survival and morbidities were compared between patients with and without mitochondrial disease. RESULTS: A total of 1330 patients were included, including 47 (3.5%) with mitochondrial disease. Survival after heart transplantation was similar between patients with and without mitochondrial disease over a median follow-up of 4 years. Patients with mitochondrial disease were more likely to have a stroke after heart transplantation (11% vs 3%; P = .009), require a longer duration of mechanical ventilation after heart transplantation (3 days vs 1 day; P < .001), and have a longer intensive care unit stay after heart transplantation (10 vs 6 days; P = .007). The absence of a hospital readmission within the first post-transplant year was similar among patients with and without mitochondrial disease (61.7% vs 51%; P = .14). However, patients with mitochondrial disease who were readmitted demonstrated a longer length of stay compared with those without (median, 14 days vs 8 days; P = .03). CONCLUSIONS: Patients with mitochondrial disease can successfully undergo heart transplantation with survival comparable with patients without mitochondrial disease. Patients with mitochondrial disease have greater risk for post-heart transplantation morbidities including stroke, prolonged mechanical ventilation, and longer intensive care unit and readmission length of stay. These results suggest that the presence of mitochondrial disease should not be an absolute contraindication to heart transplantation in the appropriate clinical setting.
OBJECTIVES: To compare the outcomes and comorbidities of children with mitochondrial disease undergoing heart transplantation with children without mitochondrial disease. STUDY DESIGN: Using a unique linkage between the Pediatric Health Information System and Scientific Registry of Transplant Recipients databases, pediatric heart transplantation recipients from 2002 to 2016 with a diagnosis of cardiomyopathy were included. Post heart transplantation survival and morbidities were compared between patients with and without mitochondrial disease. RESULTS: A total of 1330 patients were included, including 47 (3.5%) with mitochondrial disease. Survival after heart transplantation was similar between patients with and without mitochondrial disease over a median follow-up of 4 years. Patients with mitochondrial disease were more likely to have a stroke after heart transplantation (11% vs 3%; P = .009), require a longer duration of mechanical ventilation after heart transplantation (3 days vs 1 day; P < .001), and have a longer intensive care unit stay after heart transplantation (10 vs 6 days; P = .007). The absence of a hospital readmission within the first post-transplant year was similar among patients with and without mitochondrial disease (61.7% vs 51%; P = .14). However, patients with mitochondrial disease who were readmitted demonstrated a longer length of stay compared with those without (median, 14 days vs 8 days; P = .03). CONCLUSIONS:Patients with mitochondrial disease can successfully undergo heart transplantation with survival comparable with patients without mitochondrial disease. Patients with mitochondrial disease have greater risk for post-heart transplantation morbidities including stroke, prolonged mechanical ventilation, and longer intensive care unit and readmission length of stay. These results suggest that the presence of mitochondrial disease should not be an absolute contraindication to heart transplantation in the appropriate clinical setting.
Authors: F M Santorelli; M G Gagliardi; C Dionisi-Vici; F Parisi; A Tessa; R Carrozzo; F Piemonte; K Pfeiffer; H Schägger; E Bertini Journal: Neuromuscul Disord Date: 2002-01 Impact factor: 4.296
Authors: Justin Godown; Cary Thurm; Debra A Dodd; Jonathan H Soslow; Brian Feingold; Andrew H Smith; Bret A Mettler; Bryn Thompson; Matt Hall Journal: Am Heart J Date: 2017-08-23 Impact factor: 4.749
Authors: Fernando Scaglia; Jeffrey A Towbin; William J Craigen; John W Belmont; E O'Brian Smith; Stephen R Neish; Stephanie M Ware; Jill V Hunter; Susan D Fernbach; Georgirene D Vladutiu; Lee-Jun C Wong; Hannes Vogel Journal: Pediatrics Date: 2004-10 Impact factor: 7.124
Authors: Sumit Parikh; Amel Karaa; Amy Goldstein; Yi S Ng; Grainne Gorman; Annette Feigenbaum; John Christodoulou; Richard Haas; Mark Tarnopolsky; Bruce K Cohen; David Dimmock; Tim Feyma; Mary K Koenig; Helen Mundy; David Niyazov; Russell P Saneto; Mark S Wainwright; Courtney Wusthoff; Robert McFarland; Fernando Scaglia Journal: Mol Genet Metab Date: 2016-04-20 Impact factor: 4.797
Authors: Matthew G D Bates; Victoria Nesbitt; Richard Kirk; Langping He; Emma L Blakely; Charlotte L Alston; Malcolm Brodlie; Asif Hasan; Robert W Taylor; Robert McFarland Journal: Int J Cardiol Date: 2011-12-20 Impact factor: 4.164
Authors: Gregory Webster; Meredith Reynolds; Nicoleta C Arva; Lisa M Dellefave-Castillo; Hilary S McElligott; Amber Kofman; Aleksandra Laboski; Defne Magnetta; Alfred L George; Elizabeth M McNally; Megan J Puckelwartz Journal: Am J Med Genet A Date: 2021-05-18 Impact factor: 2.578
Authors: Martin Zschirnt; Josef Thul; Hakan Akintürk; Klaus Valeske; Dietmar Schranz; Susanne Skrzypek; Matthias Müller; Christian Jux; Andreas Hahn; Stefan Rupp Journal: J Pers Med Date: 2020-11-27